fda drug safety communication semaglutide naion 2025 GLP-1 RAs and NAION: New study in AJO Ozempic Vision Loss Warning: EMA
Description
El estudio se publica en Annals of Internal Medicine
If this affects you, try injecting in the morning rather than the evening
Biller, B
GLP-1 receptor agonists like semaglutide and liraglutide have transformed type 2 diabetes and weight management, but questions persist about their effects on skeletal health
Patients receive DEXA scans to track fat mass, lean muscle, and changes in body weight, not just the number on the scale
This includes allergic reactions and severe gastrointestinal discomfort or issues, which may require prompt medical attention and monitoring
